Pozen seeks FDA approval for layered aspirin cardiovascular treatment

For patients with cardiovascular disease, aspirin has become a standard of care in preventing a second heart attack or stroke, but for some, side effects can include gastrointestinal bleeding. Pozen ($POZN) submitted an application with the FDA for a tablet that combines the gastrointestinal drug omeprazole and an asipirin core coated with a pH-sensitive material. The layered treatment would allow patients to undergo aspirin therapy without the complications, according to the company. Release

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…